Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 841 to 846 of 846 entries
Sorted by: Best Match Show Resources per page
Prognostic value of the nodal yield in elective neck dissections in patients with head and neck carcinomas.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

León X, Venegas MDP, Casasayas M, Rodríguez C, Neumann ED, Holgado A, Quer M.
PMID: 33938992
Eur Arch Otorhinolaryngol. 2021 May 03; doi: 10.1007/s00405-021-06819-0. Epub 2021 May 03.

PURPOSE: The objective of this study is to assess the prognostic capacity of the nodal yield in elective neck dissections performed in patients with head and neck squamous cell carcinomas (HNSCC) without clinical or radiological evidence of regional involvement...

Cite
León X, Venegas MDP, Casasayas M, et al. Prognostic value of the nodal yield in elective neck dissections in patients with head and neck carcinomas. Eur Arch Otorhinolaryngol. 2021;doi: 10.1007/s00405-021-06819-0.
León, X., Venegas, M. D. P., Casasayas, M., Rodríguez, C., Neumann, E. D., Holgado, A., & Quer, M. (2021). Prognostic value of the nodal yield in elective neck dissections in patients with head and neck carcinomas. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, . https://doi.org/10.1007/s00405-021-06819-0
León, Xavier, et al. "Prognostic value of the nodal yield in elective neck dissections in patients with head and neck carcinomas." European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery vol. (2021). doi: https://doi.org/10.1007/s00405-021-06819-0
León X, Venegas MDP, Casasayas M, Rodríguez C, Neumann ED, Holgado A, Quer M. Prognostic value of the nodal yield in elective neck dissections in patients with head and neck carcinomas. Eur Arch Otorhinolaryngol. 2021 May 03; doi: 10.1007/s00405-021-06819-0. Epub 2021 May 03. PMID: 33938992.
Copy Download .nbib Format: NLM
Anxiety, Reinforcement Sensitivity and Social Context in Accepting the Experience of Pain Among Rheumatoid Arthritis Patients.

Frontiers in psychiatry

Pinel L, Perez-Nieto MA, Redondo M, Rodríguez-Rodríguez L, León L.
PMID: 33324249
Front Psychiatry. 2020 Nov 25;11:554990. doi: 10.3389/fpsyt.2020.554990. eCollection 2020.

No abstract available.

Cite
Pinel L, Perez-Nieto MA, Redondo M, et al. Anxiety, Reinforcement Sensitivity and Social Context in Accepting the Experience of Pain Among Rheumatoid Arthritis Patients. Front Psychiatry. 2020;11:554990doi: 10.3389/fpsyt.2020.554990.
Pinel, L., Perez-Nieto, M. A., Redondo, M., Rodríguez-Rodríguez, L., & León, L. (2020). Anxiety, Reinforcement Sensitivity and Social Context in Accepting the Experience of Pain Among Rheumatoid Arthritis Patients. Frontiers in psychiatry, 11554990. https://doi.org/10.3389/fpsyt.2020.554990
Pinel, Luis, et al. "Anxiety, Reinforcement Sensitivity and Social Context in Accepting the Experience of Pain Among Rheumatoid Arthritis Patients." Frontiers in psychiatry vol. 11 (2020): 554990. doi: https://doi.org/10.3389/fpsyt.2020.554990
Pinel L, Perez-Nieto MA, Redondo M, Rodríguez-Rodríguez L, León L. Anxiety, Reinforcement Sensitivity and Social Context in Accepting the Experience of Pain Among Rheumatoid Arthritis Patients. Front Psychiatry. 2020 Nov 25;11:554990. doi: 10.3389/fpsyt.2020.554990. eCollection 2020. PMID: 33324249; PMCID: PMC7723888.
Copy Download .nbib Format: NLM
Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.

Clinical lymphoma, myeloma & leukemia

Combariza JF, Arango M, Díaz L, Agudelo C, Hernandez S, Madera AM, León G, Avila V, Bautista L, Valdés J, Orduz R, Mejía F, Moreno L, Ramirez C.
PMID: 33277225
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e365-e372. doi: 10.1016/j.clml.2020.11.010. Epub 2020 Nov 14.

INTRODUCTION: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. The objective of the study was to assess disease-free survival (DFS) and overall survival (OS) of patients with ALL...

Cite
Combariza JF, Arango M, Díaz L, et al. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia. Clin Lymphoma Myeloma Leuk. 2020;21(4):e365-e372doi: 10.1016/j.clml.2020.11.010.
Combariza, J. F., Arango, M., Díaz, L., Agudelo, C., Hernandez, S., Madera, A. M., León, G., Avila, V., Bautista, L., Valdés, J., Orduz, R., Mejía, F., Moreno, L., & Ramirez, C. (2021). Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia. Clinical lymphoma, myeloma & leukemia, 21(4), e365-e372. https://doi.org/10.1016/j.clml.2020.11.010
Combariza, Juan Felipe, et al. "Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia." Clinical lymphoma, myeloma & leukemia vol. 21,4 (2021): e365-e372. doi: https://doi.org/10.1016/j.clml.2020.11.010
Combariza JF, Arango M, Díaz L, Agudelo C, Hernandez S, Madera AM, León G, Avila V, Bautista L, Valdés J, Orduz R, Mejía F, Moreno L, Ramirez C. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e365-e372. doi: 10.1016/j.clml.2020.11.010. Epub 2020 Nov 14. PMID: 33277225.
Copy Download .nbib Format: NLM
Identification and Characterization of Xanthomonas arboricola pv. juglandis Causing Bacterial Blight of Walnuts in Korea.

The plant pathology journal

Kim HS, Cheon W, Lee Y, Kwon HT, Seo ST, Balaraju K, Jeon Y.
PMID: 33866756
Plant Pathol J. 2021 Apr;37(2):137-151. doi: 10.5423/PPJ.OA.12.2020.0217. Epub 2021 Apr 01.

The present study describes the bacterial blight of walnut, caused by Xanthomonas arboricola pv. juglandis (Xaj) in the northern Gyeongbuk province, Korea. Disease symptoms that appear very similar to anthracnose symptoms were observed in walnut trees in June 2016....

Cite
Kim HS, Cheon W, Lee Y, et al. Identification and Characterization of Xanthomonas arboricola pv. juglandis Causing Bacterial Blight of Walnuts in Korea. Plant Pathol J. 2021;37(2):137-151doi: 10.5423/PPJ.OA.12.2020.0217.
Kim, H. S., Cheon, W., Lee, Y., Kwon, H. T., Seo, S. T., Balaraju, K., & Jeon, Y. (2021). Identification and Characterization of Xanthomonas arboricola pv. juglandis Causing Bacterial Blight of Walnuts in Korea. The plant pathology journal, 37(2), 137-151. https://doi.org/10.5423/PPJ.OA.12.2020.0217
Kim, Hyun Sup, et al. "Identification and Characterization of Xanthomonas arboricola pv. juglandis Causing Bacterial Blight of Walnuts in Korea." The plant pathology journal vol. 37,2 (2021): 137-151. doi: https://doi.org/10.5423/PPJ.OA.12.2020.0217
Kim HS, Cheon W, Lee Y, Kwon HT, Seo ST, Balaraju K, Jeon Y. Identification and Characterization of Xanthomonas arboricola pv. juglandis Causing Bacterial Blight of Walnuts in Korea. Plant Pathol J. 2021 Apr;37(2):137-151. doi: 10.5423/PPJ.OA.12.2020.0217. Epub 2021 Apr 01. PMID: 33866756; PMCID: PMC8053845.
Copy Download .nbib Format: NLM
Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab.

Clinical & translational immunology

Caballero A, Filgueira LM, Betancourt J, Sánchez N, Hidalgo C, Ramírez A, Martinez A, Despaigne RE, Escalona A, Diaz H, Meriño E, Ortega LM, Castillo U, Ramos M, Saavedra D, García Y, Lorenzo G, Cepeda M, Arencibia M, Cabrera L, Domecq M, Estévez D, Valenzuela C, Lorenzo P, Sánchez L, Mazorra Z, León K, Crombet T.
PMID: 33304584
Clin Transl Immunology. 2020 Nov 25;9(11):e1218. doi: 10.1002/cti2.1218. eCollection 2020.

OBJECTIVES: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on mature T lymphocytes which is a crucial regulator of the T-cell activation. Itolizumab is a humanised antibody targeting CD6. Nonclinical and clinical data in autoimmune...

Cite
Caballero A, Filgueira LM, Betancourt J, et al. Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab. Clin Transl Immunology. 2020;9(11):e1218doi: 10.1002/cti2.1218.
Caballero, A., Filgueira, L. M., Betancourt, J., Sánchez, N., Hidalgo, C., Ramírez, A., Martinez, A., Despaigne, R. E., Escalona, A., Diaz, H., Meriño, E., Ortega, L. M., Castillo, U., Ramos, M., Saavedra, D., García, Y., Lorenzo, G., Cepeda, M., Arencibia, M., Cabrera, L., Domecq, M., Estévez, D., Valenzuela, C., Lorenzo, P., Sánchez, L., Mazorra, Z., León, K., & Crombet, T. (2020). Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab. Clinical & translational immunology, 9(11), e1218. https://doi.org/10.1002/cti2.1218
Caballero, Armando, et al. "Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab." Clinical & translational immunology vol. 9,11 (2020): e1218. doi: https://doi.org/10.1002/cti2.1218
Caballero A, Filgueira LM, Betancourt J, Sánchez N, Hidalgo C, Ramírez A, Martinez A, Despaigne RE, Escalona A, Diaz H, Meriño E, Ortega LM, Castillo U, Ramos M, Saavedra D, García Y, Lorenzo G, Cepeda M, Arencibia M, Cabrera L, Domecq M, Estévez D, Valenzuela C, Lorenzo P, Sánchez L, Mazorra Z, León K, Crombet T. Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab. Clin Transl Immunology. 2020 Nov 25;9(11):e1218. doi: 10.1002/cti2.1218. eCollection 2020. PMID: 33304584; PMCID: PMC7688906.
Copy Download .nbib Format: NLM
Detection of Plasmodium vivax using Automated Hematology Analyzer in the Korean Army.

Clinical laboratory

Yun SG, Yoon J, Kim K, Choi JM, Jeon Y, Kim GA, Choi MK, Cho Y, Lee CK, Lim CS.
PMID: 35023668
Clin Lab. 2022 Jan 01;68(1). doi: 10.7754/Clin.Lab.2021.210301.

BACKGROUND: This study aimed to evaluate whether our equation model developed from the Sysmex hematology analyzer can discriminate patients with Plasmodium vivax (P. vivax) infection from those with acute febrile illness (AFI) and healthy controls. Besides, we compared our...

Cite
Yun SG, Yoon J, Kim K, et al. Detection of Plasmodium vivax using Automated Hematology Analyzer in the Korean Army. Clin Lab. 2022;68(1)doi: 10.7754/Clin.Lab.2021.210301.
Yun, S. G., Yoon, J., Kim, K., Choi, J. M., Jeon, Y., Kim, G. A., Choi, M. K., Cho, Y., Lee, C. K., & Lim, C. S. (2022). Detection of Plasmodium vivax using Automated Hematology Analyzer in the Korean Army. Clinical laboratory, 68(1), . https://doi.org/10.7754/Clin.Lab.2021.210301
Yun, Seung Gyu, et al. "Detection of Plasmodium vivax using Automated Hematology Analyzer in the Korean Army." Clinical laboratory vol. 68,1 (2022). doi: https://doi.org/10.7754/Clin.Lab.2021.210301
Yun SG, Yoon J, Kim K, Choi JM, Jeon Y, Kim GA, Choi MK, Cho Y, Lee CK, Lim CS. Detection of Plasmodium vivax using Automated Hematology Analyzer in the Korean Army. Clin Lab. 2022 Jan 01;68(1). doi: 10.7754/Clin.Lab.2021.210301. PMID: 35023668.
Copy Download .nbib Format: NLM
Showing 841 to 846 of 846 entries